General aspects of neurodegeneration

Journal of Neural Transmission, Supplement

Volumn , Issue 65, 2003, Pages 101-144

  Jellinger, K A ^a  

^a INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CYTOSKELETON PROTEIN; FREE RADICAL; MITOCHONDRIAL DNA; POLYGLUTAMINE; PROTEASOME; SYNUCLEIN; TAU PROTEIN; UBIQUITIN; IRON; NERVE PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; BIOENERGY; BRAIN MITOCHONDRION; CELL ACTIVATION; CELL DAMAGE; CELL DEATH; CELL INCLUSION; CELL LOSS; CONFERENCE PAPER; DEGENERATIVE DISEASE; DEMENTIA; DENTATORUBROPALLIDOLUYSIAN ATROPHY; DOWN SYNDROME; ENZYME ACTIVATION; ENZYME INHIBITION; GENE MUTATION; HALLERVORDEN SPATZ DISEASE; HUMAN; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; LEWY BODY; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; NERVE DEGENERATION; NEUROGENIC INFLAMMATION; NEUROPATHOLOGY; NIEMANN PICK DISEASE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SHY DRAGER SYNDROME; SIGNAL TRANSDUCTION; SPINOCEREBELLAR DEGENERATION; UBIQUITINATION; ANIMAL; GENETICS; GLIA; METABOLISM; MITOCHONDRION; MUTATION; NERVE CELL; PATHOLOGY; REVIEW;

ANIMALS; CELL DEATH; DNA, MITOCHONDRIAL; HUMANS; INCLUSION BODIES; IRON; MITOCHONDRIA; MUTATION; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NEUROGLIA; NEURONS; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; UBIQUITINS;

EID: 0142010013     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-0643-3_7     Document Type: Conference Paper

References (201)

1. Abramova EB, Sharova NP, Karpov VL (2002) The proteasome: destroy to live. Mol Biol 36: 613-624
2. Albers DS, Beal MF (2000) Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J Neural Transm [Suppl] 59: 133-154
3. Albers DS, Swerdlow RH, Manfredi G, Gajewski C, Yang L, Parker WD Jr, Beal MF (1999) Further evidence for mitochondrial dysfunction in progressive supranuclear palsy. Exp Neurol 168: 196-198
4. Alim MA, Hossain MS, Arima K, Takeda K, Izumiyama Y, Nakamura M, Kaji H, Shinoda T, Hisanaga S, Ueda K (2002) Tubulin seeds α-synuclein fibril formation. J Biol Chem 277: 2112-2117
5. Appel SH, Smith RG (2001) The pathogenesis of amyotrophic lateral sclerosis. In: Mattson MP (ed) Pathogenesis of neurodegenerative disorders. Human Press, Totowa, pp 149-171
6. Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y (2001) α-Synuclein-positive structures in cases with sporadic Alzheimer's disease: morphology and its relationship to tau aggregation. Brain Res 888: 287-296
7. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM (2002) Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295: 865-868
8. Beal MF (2000a) Energetics in the pathogenesis of neurodegenerative diseases. TINS 23: 298-304
9. Beal MF (2000b) Mitochondria and the pathogenesis of ALS. Brain 123: 1291-1292
10. Beckman JS, Estévez AG, Crow JP, Barbeito L (2001) Superoxide dismutase and the death of motoneurons in ALS. TINS 24 [Suppl]: S15-S20
11. Bence N, Roopal M (2001) Impairment of the ubiquitin-protease system by protein aggregation. Science 292: 1552-1554
12. Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292: 1552-1555
13. Bharath S, Hsu M, Kaur D, Rajagopalan S, Andersen JK (2002) Glutathione, iron and Parkinson's disease. Biochem Pharmacol 64: 1037-1048
14. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65: 135-172
15. Bogdanov MB, Andreassen OA, Dedeoglu A, Ferrante RJ, Beal MF (2001) Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J Neurochem 79: 1246-1249
16. Borghi R, Giliberto L, Assini A, Delacourte A, Perry G, Smith MA, Strocchi P, Zaccheo D, Tabaton M (2002) Increase of cdk5 is related to neurofibrillary pathology in progressive supranuclear palsy. Neurology 58: 589-592
17. Borthwick GM, Johnson MA, Ince PG, Shaw PJ, Turnbull DM (1999) Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann Neurol 46: 787-790
18. Boutajangout A, Leroy K, Touchet N, Authelet M, Blanchard V, Tremp G, Pradier L, Brion JP (2002) Increased tau phosphorylation but absence of formation of neurofibrillary tangles in mice double transgenic for human tau and Alzheimer mutant (M146L) presenilin-1. Neurosci Lett 318: 29-33
19. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259
20. Bratton SB, Cohen GM (2001) Apoptotic death sensor: an organelle's alter ego? Trends Pharmacol Sci 22: 306-315
21. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416: 507-511
22. Burke RF (2002) Apoptosis. In: Factor SA, Weiner WJ (eds) Parkinson's disease. Diagnosis and management. Demos, New York, pp 291-298
23. Butterfield D (2002) Amyloid β-peptide (1-42)-induced oxidative stress and neurotoxicity: Implications for neurodegeneration in Alzheimer disease brain. Free Radic Res 36: 1307-1313
24. Calingasan NY, Park LC, Calo LL, Trifiletti RR, Gandy SE, Gibson GE (1998) Induction of nitric oxide synthase and microglial responses precede selective cell death induced by chronic impairment of oxidative metabolism. Am J Pathol 153: 599-610
25. Castellani RJ, Perry G, Siedlak SL, Nunomura A, Shimohama S, Zhang J, Montine T, Sayre LM, Smith MA (2002) Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci Lett 319: 25-8
26. Castellani RJ, Siedlak SL, Perry G, Smith MA (2000) Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol 100: 111-114
27. Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F, Sipione S (2001) Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci 24: 182-188
28. Chan HY, Warrick JM, Gray-Board GL, Paulson HL, Bonini NM (2000) Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila. Hum Mol Genet 9: 2811-2820
29. Chiti F, Calamai M, Taddei N, Stefani M, Ramponi G, Dobson CM (2002) Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases. Proc Natl Acad Sci USA 99 Suppl 4: 16419-16426
30. Chung KKK, Dawson VL, Dawson TM (2001) The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. TINS 24 [Suppl]: S7-S14
31. Citron BA, Suo Z, SantaCruz K, Davies PJ, Qin F, Festoff BW (2001) Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration. Neurochem Int 40: 69-78
32. Clarke G, Collins RA, Leavitt BR, Andrews DF, Hayden MR, Lumsden CJ, McInnes RR (2000) A one-hit model of cell death in inherited neuronal degenerations. Nature 406: 195-199
33. Clayton DF, George JM (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res 58: 120-129
34. Cluskey S, Ramsden DB (2001) Mechanisms of neurodegeneration in amyotrophic lateral sclerosis. Mol Pathol 54: 386-392
35. Dickson DW (2001) Progressive supranuclear palsy and corticobasal degeneration. In: Hof RR, Mobbs LCK (eds) Functional neurobiology of aging. Academic Press, San Diego, pp 155-171
36. Dikranian K, Ishimaru MJ, Tenkova T, Labruyere J, Qin YQ, Ikonomidou C, Olney JW (2001) Apoptosis in the in vivo mammalian forebrain. Neurobiol Dis 8: 359-379
37. Double KL, Ben-Shachar D, Youdim MB, Zecca L, Riederer P, Gerlach M (2002) Influence of neuromelanin on oxidative pathways within the human substantia nigra. Neurotoxicol Teratol 24: 621-628
38. Duda JE, Lee VMY, Trojanowski JQ (2000) Neuropathology of synuclein aggregates. New insights into mechanism of neurodegenerative diseases. J Neurosci Res 61: 121-127
39. Egana JT, Zambrano C, Nunez MT, Gonzalez-Billault C, Maccioni RB (2003) Iron-induced oxidative stress modify tau phosphorylation patterns in hippocampal cell cultures. Biometals 16: 215-223
40. Elkon H, Don J, Melamed E, Ziv I, Shirvan A, Offen D (2002) Mutant and wild-type α-synuclein interact with mitochondrial cytochrome C oxidase. J Mol Neurosci 18: 229-238
41. Feany MB, Bender WW (2000) A Drosophila model of Parkinson's disease. Nature 404: 394-398
42. Ferreira ST, De Felice FG (2001) PABMB Lecture. Protein dynamics, folding and misfolding: from basic physical chemistry to human conformational diseases. FEBS Lett 498: 129-134
43. Ferrer I, Blanco R, Carmona M, Puig B, Barrachina M, Gomez C, Ambrosio S (2001) Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies. J Neural Transm 108: 1383-1396
44. Floyd RA (1999) Neuroinflammatory processes are important in neurodegenerative diseases: an hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development. Free Radic Biol Med 26: 1346-1355
45. Forloni G, Terreni L, Bertani I, Fogliarino S, Invernizzi R, Assini A, Ribizzi G, Negro A, Calabrese E, Volonte MA, Mariani C, Franceschi M, Tabaton M, Bertoli A (2002) Protein misfolding in Alzheimer's and Parkinson's disease: genetics and molecular mechanisms. Neurobiol Aging 23: 957-976
46. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T (2002) α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4: 160-164
47. Furukawa Y, Vigouroux S, Wong H, Guttman M, Rajput AH, Ang L, Briand M, Kish SJ, Briand Y (2002) Brain proteasomal function in sporadic Parkinson's disease and related disorders. Ann Neurol 51: 779-782
48. Gai WP, Yuan HX, Li XQ, Power JT, Blumbergs PC, Jensen PH (2000) In situ and in vitro study of colocalization and segregation of α-synuclein, ubiquitin, and lipids in Lewy bodies. Exp Neurol 166: 324-333
49. Galvin JE, Lee VM, Trojanowski JQ (2001) Synucleinopathies: clinical and pathological implications. Arch Neurol 58: 186-190
50. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B (2002) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 81: 1285-1297
51. Gatto EM, Riobo NA, Carreras MC, Chernavsky A, Rubio A, Satz ML, Poderoso JJ (2000) Overexpression of neutrophil neuronal nitric oxide synthase in Parkinson's disease. Nitric Oxide 4: 534-539
52. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM (2000) Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 290: 985-989
53. Giasson BI, Ischiropoulos H, Lee VM, Trojanowski JQ (2002) The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. Free Radic Biol Med 32: 1264-1275
54. Gleckman AM, Jiang Z, Liu Y, Smith TW (1999) Neuronal and glial DNA fragmentation in Pick's disease. Acta Neuropathol 98: 55-61
55. Goedert M, Jakes R, Crowther RA, Spillantini MG (2001) Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy as α-synucleinopathies. In: Mouradian MM (ed) Parkinson's disease: methods and protocols. Humana Press Inc., Totawa, pp 33-59
56. Golbe LI (2002) Neurodegeneration in the age of molecular biology. BMJ 324: 1467-1468
57. Goldberg MS, Lansbury PT Jr (2000) Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson's disease? Nat Cell Biol 2: E115-E119
58. Gómez-Tortosa E, Gonzalo I, Newell K, Yébenes JG, Vonsattel JP, Hyman BT (2002) Patterns of protein nitration in dementia with Lewy bodies and striatonigral degeneration. Acta Neuropathol 103: 495-500
59. Götz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Aβ 42 fibrils. Science 293: 1491-1495
60. Greenamyre JT, MacKenzie G, Peng TI, Stephans SE (1999) Mitochondrial dysfunction in Parkinson's disease. Biochem Soc Symp 66: 85-97
61. Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, Roberts GW, Mrak RE (1998) Glial-neuronal interactions in Alzheimer's disease: the potential role of a "cytokine cycle" in disease progression. Brain Pathol 8: 65-72
62. Grimaldi LM, Casadei VM, Ferri C, Veglia F, Licastro F, Annoni G, Biunno I, De Bellis G, Sorbi S, Mariani C, Canal N, Griffin WS, Franceschi M (2000) Association of early-onset Alzheimer's disease with an interleukin-1alpha gene polymorphism. Ann Neurol 47: 361-365
63. Gu G, Reyes PE, Golden GT, Woltjer RL, Hulette C, Montine TJ, Zhang J (2002) Mitochondrial DNA deletions/rearrangements in parkinson disease and related neurodegenerative disorders. J Neuropathol Exp Neurol 61: 634-639
64. Guo Q, Sebastian L, Sopher BL, Miller MW, Glazner GW, Ware CB, Martin GM, Mattson MP (1999) Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Proc Natl Acad Sci USA 96: 4125-4130
65. Halliwell B (2001) Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18: 685-716
66. Hansen L, Masliah E (2001) Neurobiology of disorders with Lewy bodies. In: Hof RR, Mobbs LCK (eds) Functional neurobiology of aging. Academic Press, San Diego, pp 173-182
67. Hartmann A, Mouatt-Prigent A, Vila M, Abbas N, Perier C, Faucheux BA, Vyas S, Hirsch EC (2002) Increased expression and redistribution of the antiapoptotic molecule Bcl-xL in Parkinson's disease. Neurobiol Dis 10: 28-32
68. Hartmann-Petersen R, Hendil KB, Gordon C (2003) Ubiquitin binding proteins protect ubiquitin conjugates from disassembly. FEBS Lett 535: 77-81
69. Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee VM, Trojanowski JQ, Mann D, Iwatsubo T (2002) Phosphorylated α-synuclein is ubiquitinated in α-synucleinopathy lesions. J Biol Chem 277: 49071-49076
70. Hashimoto M, Masliah E (1999) α-Synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol 9: 707-720
71. Henry JM, Jellinger KA (2003) Postencephalitic parkinsonism. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
72. Ho L, Pieroni C, Winger D, Purohit DP, Aisen PS, Pasinetti GM (1999) Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J Neurosci Res 57: 295-303
73. Hoffner G, Djian P (2002) Protein aggregation in Huntington's disease. Biochimie 84: 273-278
74. Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, Wong J, Takenoucnik T, Hashimoto M, Masliah E (2000) α-Synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 157: 401-440
75. Iha N, Jurma OP, Lalli G, Liu Y, Pettus EH, Greenamyre JT, Liu RM, Forman HJ, Andersen JK (2000) Gluthathione depletion in PC12 results in selective inhibitation of mitochondrial complex I activity: implications for Parkinson's disease. J Biol Chem 275: 26096-26101
76. Ince PG, McKeith IG (2003) Dementia with Lewy bodies. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
77. Iwata A, Maruyama M, Kanazawa I, Nukina N (2001) α-Synuclein affects the MAPK pathway and accelerates cell death. J Biol Chem 276: 45320-45329
78. Jellinger KA (2001) Cell death mechanisms in neurodegeneration. J Cell Mol Med 5: 1-17
79. Jellinger KA (2003a) Apoptosis vs. non-apoptotic mechanisms in neurodegeneration. In: Wood PL (ed) Neuroinflammation, 2nd ed. Humana Press, Totowa, pp 29-88
80. Jellinger KA (2003b) Experimental models of synucleinopathies. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
81. Jellinger KA, Duda J (2003) Neuroaxonal dystrophies. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
82. Jellinger KA, Mizuno Y (2003) Parkinson disease. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
83. Johnson WG (2001) Late-onset neujrodegenerative diseases - the role of protein insolubility. J Anat 196: 609-616
84. Kaiser P, Flick K, Wittenberg C, Reed SI (2000) Regulation of transcription by ubiquitination without proteolysis: Cdc34/SCF(Met30)-mediated inactivation of the transcription factor Met4. Cell 102: 303-314
85. Katayama S, Watanabe C, Kohriyama T, Yamamura Y, Mao JJ, Ohishi H, Nishisaka T, Inai K, Tanaka E, Nakamura S (2000) Gallyas-positive argyrophilic and ubiquitinated filamentous inclusions in rapidly progressive motor neuron disease: immunohistochemical and electron microscopic studies. Acta Neuropathol 100: 221-227
86. Ke Y, Qian ZM (2003) Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol 2: 246-252
87. Kikuchi A, Takeda A, Onodera H, Kimpara T, Hisanaga K, Sato N, Nunomura A, Castellani RJ, Perry G, Smith MA, Itoyama Y (2002) Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis 9: 244-248
88. Kim HT, Russell RL, Raina AK, Harris PL, Siedlak SL, Zhu X, Petersen RB, Shimohama S, Smith MA, Perry G (2000) Protein disulfide isomerase in Alzheimer disease. Antioxid Redox Signal 2: 485-489
89. Kim KS, Choi SY, Kwon HY, Won MH, Kang TC, Kang JH (2002) The ceruloplasmin and hydrogen peroxide system induces alpha-synuclein aggregation in vitro. Biochimie 84: 625-631
90. Kim SH, Creemers JW, Chu S, Thinakaran G, Sisodia SS (2002) Proteolytic processing of familial British dementia-associated BRI variants: evidence for enhanced intracellular accumulation of amyloidogenic peptides. J Biol Chem 277: 1872-1877
91. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605-608
92. Klement IA, Skinner PJ, Kaytor MD, Yi H, Hersch SM, Clark HB, Zoghbi HY, Orr HT (1998) Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95: 41-53
93. Kopito RR (2000) Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 10: 524-350
94. Kovacs GG, Kloppel S, Fischer I, Dorner S, Lindeck-Pozza E, Birner P, Botefur IC, Pilz P, Volk B, Budka H (2003) Nucleus-specific alteration of raphe neurons in human neurodegenerative disorders. Neuroreport 14: 73-76
95. Krieger C, Duchen MR (2002) Mitochondria, Ca(2+) and neurodegenerative disease. Eur J Pharmacol 447: 177-188
96. Kril JJ, Halliday GM (2001) Alzheimer's disease: its diagnosis and pathogenesis. Int Rev Neurobiol 48: 167-217
97. Lantos PL, Quinn N (2003) Dementia with Lewy bodies. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
98. Lassmann H, Bancher C, Breitschopf H, Wegiel J, Bobinski M, Jellinger K, Wisniewski HM (1995) Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol 89: 35-41
99. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH (2000) Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405: 360-364
100. Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24: 1121-1159
101. Linert W, Jellinger KA (2001) Cell death mechanisms and the role of iron in neurodegeneration. In: Segura-Aquilar J (ed) Mechanisms of degeneration and protection of the dopaminergic system. FP Graham Publishing, Johnson City, pp 21-65
102. Lippa CF (2003) Lewy bodies in conditions other than disorders of α-synuclein. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
103. Lotharius J, Brundin P (2002) Impaired dopamine storage resulting from α-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet 11: 2395-2407
104. Lovestone S, McLoughlin DM (2002) Protein aggregates and dementia: is there a common toxicity? J Neurol Neurosurg Psychiatry 72: 152-161
105. Lovestone S, Reynolds CH (1997) The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78: 309-324
106. Mager P, Penke B, Walter R, Harkany T, Hartig W (2002) Pathological peptide folding in Alzheimer disease and other conformational disorders. Curr Med Chem 9: 1763-1780
107. Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA (2002) The herbicide paraquat causes up-regulation and aggregation of α-synuclein in mice: paraquat and α-synuclein. J Biol Chem 277: 1641-1644
108. Markesbery WR, Montine DJ, Lovell MA (2001) Oxidative alterations in neurodegenerative diseases, In: Mattson MP (ed) Pathogenesis of neurodegenerative disorders. Humana Press, Totowa, pp 21-51
109. Marx J (2001) New leads on the 'how' of Alzheimer's. Science 293: 2192-4219
110. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L (2001) β-amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 98: 12245-12250
111. Mattson MP (2001) Inflammation, free radicals, glycation, metabolism and apoptosis, heavy metals. In: Hof RR, Mobbs LCK (eds) Functional neurobiology of aging. Academic Press, San Diego, pp 349-371
112. Mattson MP (2001) Mechanisms of neuronal apoptosis and excitotoxicity. In: Mattson MP (ed) Pathogenesis of neurodegenerative disorders. Humana Press, Totowa, pp 1-20
113. McGeer PL, McGeer EG (2000) Autotoxicity and Alzheimer disease. Arch Neurol 57: 789-790
114. McGeer PL, McGeer EG (2002) Polymorphisms in inflammatory genes enhance the risk of Alzheimer disease. Alzheimer Research Forum, February 11, 2002
115. McGeer PL, Yasojima K, McGeer EG (2001) Inflammation in Parkinson's disease. Adv Neurol 86: 83-89
116. McMurray CT (2001) Huntington's disease: new hope for therapeutics. TINS 24[Suppl]: S32-S37
117. McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P (2001) Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci 2: 589-594
118. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW (2003) Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 179: 38-46
119. McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW (2002) Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci 16: 2136-2148
120. Merlini G, Bellotti V, Andreola A, Palladini G, Obici L, Casarini S, Perfetti V (2001) Protein aggregation. Clin Chem Lab Med 39: 1065-1075
121. Miake H, Mizusawa H, Iwatsubo T, Hasegawa M (2002) Biochemical characterization of the core structure of α-synuclein filaments. J Biol Chem 277: 19213-19219
122. Miller RJ, Wilson SM (2003) Neurological disease: UPS stops delivering! Trends Pharmacol Sci 24: 18-23
123. Morris HR, Katzenschlager R, Janssen JC, Brown JM, Ozansoy M, Quinn N, Revesz T, Rossor MN, Daniel SE, Wood NW, Lees AJ (2002) Sequence analysis of tau in familial and sporadic progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 72: 388-390
124. Morsch R, Simon W, Coleman PD (1999) Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 58: 188-197
125. Mrak RE, Griffin WS (2000) Interleukin-1 and the immunogenetics of Alzheimer disease. J Neuropathol Exp Neurol 59: 471-476
126. Mudher A, Lovestone S (2002) Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci 25: 22-26
127. Munch G, Luth HJ, Wong A, Arendt T, Hirsch E, Ravid R, Riederer P (2000) Crosslinking of α-synuclein by advanced glycation endproducts - an early pathophysiological step in Lewy body formation? J Chem Neuroanat 20: 253-257
128. Myung J, Kim KB, Crews CM (2001) The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 21: 245-273
129. Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, Esiri MM, Murray LS, Dewar D, Love S, Moss T, Griffin WS (2000) Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 47: 365-368
130. Nicotera P (2002) Apoptosis and age-related disorders: role of caspase-dependent and caspase-independent pathways. Toxicol Lett 127: 189-195
131. Nicotera P, Leist M, Fava E, Berliocchi L, Volbracht C (2000) Energy requirement for caspase activation and neuronal cell death. Brain Pathol 10: 276-282
132. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60: 759-767
133. Odetti P, Garibaldi S, Norese R, Angelini G, Marinelli L, Valentini S, Menini S, Traverso N, Zaccheo D, Siedlak S, Perry G, Smith MA, Tabaton M (2000) Lipoperoxidation is selectively involved in progressive supranuclear palsy. J Neuropathol Exp Neurol 59: 393-397
134. Orth M, Schapira AHV (2001) Mitochondria and degenerative disorders. Am J Med Genet 106: 27-36
135. th Int Conf on Alzheimer disease
136. Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmond MJ (2002) A role for α-synuclein in the regulation of dopamine biosynthesis. J Neurosci 22: 3090-3099
137. Perry G, Liu Q, Wataya T, Shimohama S, Nunomura A, Siedlak SL, Sayre LL, Smith MA (2002) Neurofilament proteins are major targets of oxidative damage in the nervous system. J Neuropathol Exp Neurol 61: 456
138. Perry G, Srinivas R, Nunomura A, Smith MA (2003) Oxidative mechanisms in neurodegenerative diseases. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
139. th International Conference on Alzheimer disease and Related Disorders, July 19-25, 2002, Abstr. # 4235
140. Perry VH, Newman TA, Cunningham C (2003) The impact of systemic infection on the progression of neurodegenerative disease. Nat Rev Neurosci 4: 103-112
141. Pickart CM (2001) Mechanisms underlying ubiquitination. Annu Rev Biochem 70: 503-533
142. Radisky DC, Babcock MC, Kaplan J (1999) The yeast frataxin homologue mediates mitochondrial iron efflux. Evidence for a mitochondrial iron cycle. J Biol Chem 274: 4497-4499
143. Raina AK, Hochman A, Zhu X, Rottkamp CA, Nunomura A, Siedlak SL, Boux H, Castellani RJ, Perry G, Smith MA (2001) Abortive apoptosis in Alzheimer's disease. Acta Neuropathol 101: 305-310
144. nd ed. Humana Press, Totowa, NJ, pp. 225-246
145. Reddy PH, Williams M, Charles V, Garrett L, Pike-Buchanan L, Whetsell WO Jr, Miller G, Tagle DA (1998) Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet 20: 198-202
146. Reed JC (2000) Mechanisms of apoptosis. Am J Pathol 157: 1415-1430
147. Riederer P, Reichmann H, Janetzky B, Sian J, Lesch KP, Lange KW, Double KL, Nagatsu T, Gerlach M (2001) Neural degeneration in Parkinson's disease. Adv Neurol 86: 125-136
148. Rohn TT, Head E, Nesse WH, Cotman CW, Cribbs DH (2001) Activation of caspase-8 in the Alzheimer's disease brain. Neurobiol Dis 8: 1006-1016
149. Roth KA (2001) Caspases, apoptosis, and Alzheimer disease: causation, correlation, and confusion. J Neuropathol Exp Neurol 60: 829-838
150. Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, Chevion M, Perry G, Smith MA (2001) Redox-active iron mediates amyloid-β, toxicity. Free Radic Biol Med 30: 447-450
151. Saha AR, Ninkina NN, Hanger DP, Anderton BH, Davies AM, Buchman VL (2000) Induction of neuronal death by α-synuclein. Eur J Neursoci 12: 3073-3077
152. Sakamoto M, Uchihara T, Hayashi M, Nakamura A, Kikuchi E, Mizutani T, Mizusawa H, Hirai S (2002) Heterogeneity of nigral and cortical Lewy bodies differentiated by amplified triple-labeling for α-synuclein, ubiquitin, and thiazin red. Exp Neurol 177: 88-94
153. Saudou F, Finkbeiner S, Devys D, Greenberg ME (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95: 55-66
154. Sayre LM, Smith MA, Perry G (2001) Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 8: 721-738
155. Schlossmacher MG, Frosch MP, Gai WP, Medina M, Sharma N, Forno L, Ochiishi T, Shimura H, Sharon R, Hattori N, Langston JW, Mizuno Y, Hyman BT, Selkoe DJ, Kosik KS (2002) Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol 160: 1655-1667
156. Schmidt T, Lindenberg KS, Krebs A, Schöls L, Laccone F, Herms J, Rechsteiner M, Riess O, Landwehrmeyer GB (2002) Protein surveillance machinery in brains with spinocerebellar ataxia type 3: Redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions. Ann Neurol 51: 302-310
157. Schwab C, Schulzer M, Steele JC, McGeer PL (1999) On the survival time of a tangled neuron in the hippocampal CA4 region in parkinsonism dementia complex of Guam. Neurobiol Aging 20: 57-63
158. Sharma N, Hewett J, Ozelius LJ, Ramesh V, McLean PJ, Breakefield XO, Hyman BT (2001) A close association of torsinA and α-synuclein in Lewy bodies: a fluorescence resonance energy transfer study. Am J Pathol 159: 339-344
159. Sherman MY, Goldberg AL (2001) Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29: 15-32
160. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ (2001) Ubiquitination of a new form of α-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293: 263-269
161. Shringarpure R, Grune T, Mehlhase J, Davies KJ (2003) Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. J Biol Chem 278: 311-318
162. Sieradzan KA, Mechan AO, Jones L, Wanker EE, Nukina N, Mann DM (1999) Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp Neurol 156: 92-99
163. Silva MT, Schapira AHV (2001) Parkinson's disease. In: Mattson MP (ed) Pathogenesis of neurodegenerative disorders. Human Press, Totowa, pp 53-79
164. Simon DK, Beal MF (2002) Pathogenesis: oxidative stress, mitochondrial dysfunction and excitotoxicity. In: Factor SA, Weiner WJ (eds) Parkinson's disease. Diagnosis and management. Demos, New York, pp 281-290
165. Sly LM, Krzesicki RF, Brashler JR, Buhl AE, McKinley DD, Carter DB, Chin JE (2001) Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res Bull 56: 581-588
166. Soto C (2001) Protein misfolding and disease; protein refolding and therapy. FEBS Lett 498: 204-207
167. Soto C (2003) Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 4: 49-60
168. Stadelmann C, Deckwerth TL, Srinivasan A, Bancher C, Bruck W, Jellinger K, Lassmann H (1999) Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am J Pathol 155: 1459-1466
169. Stewart VC, Heales SJ (2003) Nitric oxide-induced mitochondrial dysfunction: implications for neurodegeneration. Free Radic Biol Med 34: 287-303
170. Tabner BJ, Turnbull S, El-Agnaf OM, Allsop D (2002) Formation of hydrogen peroxide and hydroxyl radicals from Aβ and a-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic Biol Med 32: 1076-1083
171. Takahashi M, Weidenheim KM, Dickson DW, Ksiezak-Reding H (2002) Morphological and biochemical correlations of abnormal tau filaments in progressive supranuclear palsy. J Neuropathol Exp Neurol 61: 33-45
172. Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK (2002) Intraneuronal Alzheimer Aβ42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161: 1869-1879
173. Tatton NA (2000) Increased caspase-3 and BAX immunoreactivity accompanying nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol 166: 29-43
174. Tatton WG, Olanow CW (1999) Apoptosis in neurodegenerative disease: The role of mitochondria. Biochem Biophys Acta 1410: 195-214
175. Teismann P, Tieu K, Cohen O, Choi DK, Wu du C, Marks D, Vila M, Jackson-Lewis V, Przedborski S (2003) Pathogenic role of glial cells in Parkinson's disease. Mov Disord 18: 121-129
176. Thal DR, Rüb U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K, Braak E, Braak H (2000) Sequence of Aβ-protein deposition in the human
177. Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 58: 1781-1800
178. Thompson KJ, Shoham S, Connor JR (2001) Iron and neurodegenerative disorders. Brain Res Bull 55: 155-164
179. Tiranti V, Jaksch M, Hofmann S, Galimberti C, Hoertnagel K, Lulli L, Freisinger P, Bindoff L, Gerbitz KD, Comi GP, Uziel G, Zeviani M, Meitinger T (1999) Loss-of-function mutations of SURF-1 are specifically associated with Leigh syndrome with cytochrome c oxidase deficiency. Ann Neurol 46: 161-166
180. Tompkins MM, Hill WD (1997) Contribution of somal Lewy bodies to neuronal death. Brain Res 775: 24-29
181. Trojanowski J (2003) Protein aggregation. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
182. Trojanowski JQ, Lee VM (2000) "Fatal attractions" of proteins. A comprehensive hypothetical mechanism underlying Alzheimer's disease and other neurodegenerative disorders. Ann NY Acad Sci 924: 62-67
183. Trojanowski JQ, Lee VM (2001) Parkinson's disease and related neurodegenerative synucleinopathies linked to progressive accumulations of synuclein aggregates in brain. Parkinsonism Relat Disord 7: 247-251
184. Trojanowski JQ, Goedert M, Iwatsubo T, Lee VMY (1998) Fatal attractions - abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body-dementia. Cell Death Different 5: 832-837
185. Uversky VN (2002) What does it mean to be natively unfolded? Eur J Biochem 269: 2-12
186. Uversky VN, Li J, Fink AL (2001) Metal-triggered structural transformations, aggregation, and fibrillation of human α-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 276: 44284-44296
187. Vielhaber S, Winkler K, Kirches E, Kunz D, Buchner M, Feistner H, Elger CE, Ludolph AC, Riepe MW, Kunz WS (1999) Visualization of defective mitochondrial function in skeletal muscle fibers of patients with sporadic amyotrophic lateral sclerosis. J Neurol Sci 169: 133-139
188. Vila M, Wu DC, Przedborski S (2001) Engineered modeling and the secrets of Parkinson's disease. TINS 24[Suppl]: S49-S55
189. Walker LC, LeVine H 3rd (2002) The cerebral proteopathies. Neurobiol Aging 2000;21: 559-561
190. Wang KKW (2000) Calpain and caspase; can you tell the difference? Trends Neurol Sci 23: 20-26
191. Watanabe M, Dykes-Hoberg M, Culotta VC, Price DL, Wong PC, Rothstein JD (2001) Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol Dis 8: 933-941
192. Williams A (2002) Defining neurodegenerative diseases. BMJ 324: 1465-1466
193. Wilson CA, Doms RW, Lee VM (1999) Intracellular APP processing and Aβ production in Alzheimer disease. J Neuropathol Exp Neurol 58: 787-794
194. Wolozin B, Behl C (2000) Mechanisms of neurodegenerative disorders, part 1. Protein aggregates. Arch Neurol 57: 793-796
195. Wong A, Luth HJ, Deuther-Conrad W, Dukic-Stefanovic S, Gasic-Milenkovic J, Arendt T, Munch G (2001) Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer's disease. Brain Res 920: 32-40
196. Yamamoto A, Shin RW, Hasegawa K, Naiki H, Sato H, Yoshimasu F, Kitamoto T (2002) Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease. J Neurochem 82: 1137-1147
197. Youdim MBH, Drigues N, Mandel S (2001) Oxidative stress indices in Parkinson's disease. In: Mouradian MM (ed) Parkinson's disease: methods and protocols. Humana Press, Totowa, pp 137-153
198. Zemaitaitis MO, Kim SY, Halverson RA, Troncoso JC, Lee JM, Muma NA (2003) Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy. J Neuropathol Exp Neurol 62: 173-184
199. Zhang J, Perry G, Smith MA, Robertson D, Olson SJ, Graham DG, Montine TJ (1999) Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 154: 1423-1429
200. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ (2001) A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 28: 345-349
201. Zhou W, Schaack J, Zawada WM, Freed CR (2002) Overexpression of human α-synuclein causes dopamine neuron death in primary human mesencephalic culture. Brain Res 926: 42-50